Nanopharmaceuticals LLC
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jan 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 25, 2026The maintenance fee for Composition and method for dual targeting in treatment of neuroendocrine tumors (US 10,328,043) comes due Dec 25, 2026. Unpaid by Jun 25, 2027, it lapses early.
- 1 fee due Feb 15, 2027The maintenance fee for Polymer conjugated thyrointegrin antagonists (US 11,723,888) comes due Feb 15, 2027. Unpaid by Aug 16, 2027, it lapses early.
Recent changes
- 1 term has ended since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 10 of 10
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,580,395 | Compositions of dual thyrointegrin antagonists and use in vascular-associated disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 8,859,539 | Compositions of dual thyrointegrin antagonists and use in vascular-associated disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 10,201,616 | Non-Cleavable Polymer Conjugated with Alpha V Beta 3 Integrin Thyroid Antagonists In force · High confidence | In force | High confidence | |
| US 10,695,436 | Non-cleavable polymer conjugated with alpha V beta 3 integrin thyroid antagonists In force · From the USPTO record | In force | From the USPTO record | |
| US 10,328,043 | Composition and method for dual targeting in treatment of neuroendocrine tumors In force · From the USPTO record | In force | From the USPTO record | |
| US 11,077,082 | Composition and method for dual targeting in treatment of neuroendocrine tumors In force · From the USPTO record | In force | From the USPTO record | |
| US 11,351,137 | Composition and method for dual targeting in treatment of neuroendocrine tumors In force · From the USPTO record | In force | From the USPTO record | |
| US 10,961,204 | Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors In force · From the USPTO record | In force | From the USPTO record | |
| US 11,186,551 | Composition of scalable thyrointegrin antagonists with improved retention in tumors In force · From the USPTO record | In force | From the USPTO record | |
| US 11,723,888 | Polymer conjugated thyrointegrin antagonists In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 10: 14 lapsed for an unpaid fee · 4 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 no status recorded